Scarica l'app Stockscreener
1.17
0.86%
0.01
Precedente Chiudi:
$1.16
Aprire:
$1.14
Volume 24 ore:
54,793
Relative Volume:
0.33
Capitalizzazione di mercato:
$44.20M
Reddito:
$22.33M
Utile/perdita netta:
$-85.89M
Rapporto P/E:
-0.51
EPS:
-2.2942
Flusso di cassa netto:
$-89.47M
1 W Prestazione:
-1.68%
1M Prestazione:
-3.31%
6M Prestazione:
-26.88%
1 anno Prestazione:
-34.27%
Intervallo 1D:
$1.14
$1.1702
Intervallo di 1 settimana:
$1.1281
$1.21
Portata 52W:
$1.1281
$3.95
Metagenomi Therapeutics Inc Stock (MGX) Company Profile
Nome
Metagenomi Therapeutics Inc
Settore
Industria
Telefono
(510) 871-4880
Indirizzo
5959 HORTON STREET, EMERYVILLE
Compare MGX vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MGX
Metagenomi Therapeutics Inc
|
1.17 | 45.33M | 22.33M | -85.89M | -89.47M | -2.2942 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Metagenomi Therapeutics Inc Stock (MGX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-05-07 | Iniziato | H.C. Wainwright | Buy |
| 2024-05-02 | Downgrade | JP Morgan | Overweight → Neutral |
| 2024-03-05 | Iniziato | BMO Capital Markets | Outperform |
| 2024-03-05 | Iniziato | Chardan Capital Markets | Buy |
| 2024-03-05 | Iniziato | JP Morgan | Overweight |
| 2024-03-05 | Iniziato | Jefferies | Buy |
| 2024-03-05 | Iniziato | TD Cowen | Outperform |
| 2024-03-05 | Iniziato | Wells Fargo | Overweight |
Mostra tutto
Metagenomi Therapeutics Inc Borsa (MGX) Ultime notizie
Metagenomi Therapeutics (MGX) Holds Steady at $1.23 as Biotech Consolidates Between Key LevelsBreakout Stock Alerts - vinanet.vn
Metagenomi Therapeutics, Inc. (NASDAQ:MGX) Analysts Are Cutting Their Estimates: Here's What You Need To Know - simplywall.st
These Analysts Think Metagenomi Therapeutics, Inc.'s (NASDAQ:MGX) Sales Are Under Threat - webull.com
Analysts’ Top Healthcare Picks: Metagenomi, Inc. (MGX), Kymera Therapeutics (KYMR) - The Globe and Mail
Metagenomi Therapeutics reports $27.5M loss in Q2 2026 - scanx.trade
Metagenomi Therapeutics (MGX) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
Metagenomi Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Metagenomi Therapeutics: Q2 Earnings Snapshot - marketscreener.com
Metagenomi Therapeutics (MGX) revenue drops as losses widen but cash tops $120M - Stock Titan
Metagenomi Therapeutics Reports Business Updates and Second Quarter 2026 Financial Results - The Manila Times
Metagenomi Therapeutics Inc expected to post a loss of 57 cents a shareEarnings Preview - TradingView
MGX Q1 2026 Earnings: Wider-than-Expected Loss Highlights Pre-Revenue ChallengesQuarterly Earnings - vinanet.vn
Metagenomi Therapeutics (MGX) Edges Higher as Gene-Editing Speculation PercolatesBreakaway Gap - Vinanet
Amazon has Q2 sales of $200bn - Electronics Weekly
MGX Q1 2026 Earnings: EPS Miss Reflects Operational Progress in Gene Editing PipelineManagement Tone Analysis - Vinanet
Metagenomi Therapeutics (MGX) Proxy filing Summary - Quartr
Metagenomi Therapeutics (MGX) AGM 2026 Summary - Quartr
Metagenomi Therapeutics (MGX) Q1 2026 earnings summary - Quartr
Metagenomi Therapeutics (MGX) Slides 2.7% as Stock Tests Key Support LevelTICK Divergence - vinanet.vn
Did Metagenomi Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders? - AOL.com
Chardan Capital Initiates Metagenomi Therapeutics(MGX.US) With Buy Rating, Announces Target Price $5 - Moomoo
Chardan initiates Metagenomi stock with buy, $5 target on gene therapy potential - Investing.com
Metagenomi Therapeutics (MGX) Faces Continued Pressure Near Support LevelsSchiff Line - po-news-eg.net
Metagenomi Therapeutics (MGX) Holds Steady at $1.25 as Stock Consolidates Between Key LevelsSingle Stock ETF - dars.gov.et
Metagenomi Therapeutics (MGX) Rebounds from Support, Eyes Resistance at $1.31Price Surge Stocks - dars.gov.et
Price to sales forward of Metagenomi Therapeutics, Inc. – NASDAQ:MGX - TradingView
Enterprise value to EBIT forward of Metagenomi Therapeutics, Inc. – NASDAQ:MGX - TradingView
Price to book forward of Metagenomi Therapeutics, Inc. – NASDAQ:MGX - TradingView
Price to earnings forward of Metagenomi Therapeutics, Inc. – NASDAQ:MGX - TradingView
Metagenomi Therapeutics, Inc. Actuals & Estimates (NASDAQ:MGX) - TradingView
MGX Forecast — Price Target — Prediction for 2027 - TradingView
Metagenomi Therapeutics (MGX) Edges Lower, Testing Key Support at $1.13Sign of Strength - dars.gov.et
MGX Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Metagenomi Therapeutics Inc. (MGX) Q1 2026 Earnings: Wider-Than-Expected Loss Amid Continued Pipeline InvestmentDividend Increase Stocks - dars.gov.et
Metagenomi Therapeutics (MGX) Rebounds from Support; Faces Key Resistance at $1.26Sign of Weakness - dars.gov.et
Metagenomi Therapeutics (MGX) Edges Lower as Stock Tests Key Support ZoneBull Pennant - Město Břeclav
Metagenomi Therapeutics (MGX) director awarded 17,400 stock options at $1.23 - Stock Titan
Metagenomi Therapeutics (MGX) director awarded options on 21,000 shares - Stock Titan
Metagenomi Therapeutics (MGX) director receives 21,000-share stock option grant at $1.23 - Stock Titan
Metagenomi (NASDAQ: MGX) director receives 21,000 stock options at $1.23 strike - Stock Titan
Metagenomi CFO Pamela Wapnick sells $3,746 of company stock - Investing.com UK
Metagenomi CEO Jian Irish sells $4,854 in company stock - Investing.com UK
Metagenomi general counsel Wein sells $724 in common stock - Investing.com UK
Metagenomi CFO Pamela Wapnick sells $3,746 of company stock By Investing.com - Investing.com Australia
[Form 4] Metagenomi Therapeutics, Inc. Insider Trading Activity - Stock Titan
Tax-driven sale as Metagenomi (MGX) director Irish reports 3,737 shares sold - Stock Titan
Metagenomi Announces Board Changes and Shareholder Meeting Results - TipRanks
Metagenomi Therapeutics, Inc. Announces Resignation of Brian C. Thomas, Ph.D. as A Member of the Board, Effective as of June 9, 2026 - marketscreener.com
Brian C. Thomas resigns from Metagenomi board effective June 9, 2026 - TradingView
Metagenomi (NASDAQ: MGX) director exits as shareholders back board - Stock Titan
MGX: Directors and auditor were approved, with no stockholder questions or new nominations - TradingView
Metagenomi Therapeutics Inc Azioni (MGX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Metagenomi Therapeutics Inc Azioni (MGX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Irish Jian | See Remarks |
Jun 05 '26 |
Sale |
1.30 |
3,737 |
4,854 |
377,533 |
| Wein Matthew | See Remarks |
Jun 05 '26 |
Sale |
1.30 |
558 |
725 |
126,491 |
| Wapnick Pamela | Chief Financial Officer |
Mar 05 '26 |
Sale |
1.60 |
1,581 |
2,530 |
187,375 |
| Wein Matthew | See Remarks |
Mar 05 '26 |
Sale |
1.60 |
482 |
771 |
114,549 |
| Irish Jian | Chief Executive Officer |
Mar 05 '26 |
Sale |
1.60 |
1,607 |
2,571 |
333,770 |
| Thomas Brian C. | Director |
Dec 05 '25 |
Sale |
1.77 |
3,830 |
6,786 |
2,510,960 |
| Wein Matthew | See Remarks |
Dec 05 '25 |
Sale |
1.77 |
199 |
353 |
115,031 |
| Wapnick Pamela | Chief Financial Officer |
Dec 05 '25 |
Sale |
1.77 |
1,576 |
2,793 |
188,956 |
| Irish Jian | Chief Executive Officer |
Dec 05 '25 |
Sale |
1.77 |
1,602 |
2,839 |
563,839 |
0.86%
0.31%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):